Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC
Clinical trial NCT04718909 · UNKNOWN
Trial details
- NCT number
- NCT04718909
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-01-09
- Primary completion
- 2023-07-08
- Enrollment
- 166
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.